|
|
 |
|
Viewing report
|
|
|
|
Analytical Tool - Current & Future Lung Cancer Therapeutics
Bioseeker, May 2007
1 Executive Summary
2 Cancer Highlights
3 Methodology
4 List of Contents
4.1 List of boxes
4.2 List of tables
4.3 Appendices
5 Introduction
5.1 Current Treatment Strategies
5.2 Disease Definition
5.3 Etiology & Pathophysiology
5.4 Prognosis
5.5 Epidemiology
6 Progress in current treatment strategies
6.1 Improvements adding microtubule inhibitor
6.2 Improvement of disease related symptoms in elderly patients
6.3 Toxicity profile favoured
6.4 A new formula
6.5 Monotherapy?
6.6 Failed to demonstrate a survival advantage
6.7 Reduction in mortality risk
7 Key Drug Strategies in Lung Cancer
7.1 Apoptosis
7.2 Antiangiogenesis and Antivascular Agents
7.2.1 EGFR and VEGFR as target
7.3 Immunotherapy
8 Competitive Landscape in Lung Cancer Drug Development: The Late Stage
Pipeline
8.1 Grade 4 adverse events
8.2 No new remarks
8.3 No significant effect on overall survival
8.4 Bristol Myers Squibb entered into an agreement
8.5 Many uncertainties remain
8.6 Development terminated
8.7 Continuing Enrollment
8.8 Apoptotic inducer
8.9 Fully-human monoclonal antibody
8.10 Eagerly awaiting data
8.11 Mutations and response
8.12 Statistically and clinically significant survival advantage
8.13 Anti-idiotypic monoclonal antibody
8.14 Shift in the development focus
8.15 Sensitizer
8.16 Treatment in earlier-stage cancer could be more effective
8.17 Discontinued radiosensitizer
8.18 Improvement in chemoradiotherapy
8.19 Progress on HDAC inhibitor
8.20 Progress Analysis Carboxyamidotriazole
8.21 Chemotherapy naïve subjects
9 Disclaimer
9.1 Liability
9.2 Completeness
10 Appendix 1. Treatment Guide Lines
10.1 References
11 Appendix 2: Selected Company Profiles
11.1 Abgenix
11.2 Aphton
11.3 AstraZeneca
11.4 Bristol-Myers Squibb
11.5 Eli Lilly
11.6 Genentech
11.7 Genta
11.8 GlaxoSmithKline
11.9 ImClone
11.10 ISIS Pharmaceuticals
11.11 Ligand Pharmaceuticals
11.12 OSI Pharmaceuticals
11.13 Pfizer
11.14 Pharmacyclics
11.15 Sanofi- Aventis
11.16 Telik
12 Appendix 3 Progress profiles on approved drugs
12.1 Docetaxel
12.2 Vinorelbine
12.3 Gemcitabine
12.4 Paclitaxel
12.5 Pemetrexed
12.6 Gefitinib
12.7 Erlotinib
13 Drug Index
14 Company Index
4.1 List of boxes
Box 1: Scientific Data on Docetaxel
Box 2: Quick Facts - Vinorelbine
Box 3: Scientific Data on Vinorelbine
Box 4: Quick Facts - Gemcitabine
Box 5: Scientific Data on gemcitabine
Box 6: Scientific Data on Pemetrexed
Box 7: Quick Facts - pemetrexed
Box 8: Quick Facts - Gefitinib
Box 9: Scientific Data on Gefitinib
Box 10: Quick Facts - Erlotinib
4.2 List of tables
Table 1: Chemotherapeutic drugs for treatment of NSCLC
Table 2. Near Term Approved Drugs for the Treatment of NSCLC
Table 3: Chemotherapy Drugs off Patent
Table 4 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
Table 5 VTA agents under development
Table 6 EGFR or VEGFR inhibitors
Table 7: FMS-like tyrosine kinases and their Synonyms
Table 8: Fms-related Tyrosine Kinase Targets in Development
Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer
Table 10 Cancer immunotherapy strategies
Table 11 Recently presented studies Lapatinib
Table 12 Recently presented studies ZD-6474
Table 13 Recently presented studies vinflunine
Table 14 Recently presented studies Panitumumab
Table 15 Recently presented studies Genasense
Table 16 Recently presented studies cetuximab
Table 17 Recently presented studies bevacizumab
Table 18 Recently presented studies bexarotene
Table 19 Recently presented studies Xcytrin
4.3 Appendices
10 Appendix 1. Treatment Guide Lines
11 Appendix 2: Selected Company Profiles
12 Appendix 3 Progress profiles on approved drugs
Customers who bought this item also bought
Targeted Therapeutics in Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Cancer Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer
Current and Future Therapies For Lung Cancer - A Therapeutic & Competitive Insight
Lung Cancer, 3rd Edition
Analytical Tool - Prostate Cancer
Analytical Tool - Breast Cancer
Analytical Tool - Prostate Cancer: A Therapeutic & Competitive Insight
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report
Cancer Therapeutics Markets
|
|
|
|
